



Recent Advances and Perspectives in the Treatment of Dementia

Guest Editors:

Dr. Agnieszka Zagórska

Department of Medicinal
Chemistry, Faculty of Pharmacy,
Jagiellonian University Medical
College, Kraków, Poland

Dr. Anna Czopek

Department of Medicinal
Chemistry, Faculty of Pharmacy,
Jagiellonian University Medical
College, Kraków, Poland

Deadline for manuscript
submissions:

25 May 2024

Message from the Guest Editors

According to the World Health Organization (WHO), dementia is a syndrome in which deterioration in cognitive function beyond what might be expected from the usual consequences of biological ageing occurs. Dementia affects memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgement. Moreover, among patients with dementia, neuropsychiatric symptoms (NPS) are frequently observed.

Dementia is a complex disease with multiple etiologies and multiple treatments; however, currently available anti-dementia medicines are disease-modifying therapies and have limited efficacy. Thus, therapy for people diagnosed with dementia with antidementia compounds is still an urgent, unmet need.

The journal *Pharmaceuticals* invites both reviews and original articles that shed light on the recent advancements and perspectives in the treatment of dementia. Topics include drug repositioning, multifunctional compounds, the discovery of multitarget-directed ligands (MTDLs), computer-aided drug design, and nonpharmacologic and pharmacologic treatments in clinical trials.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [Embase](#), [CAPus / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q2 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

Contact Us

Pharmaceuticals Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceuticals
pharmaceuticals@mdpi.com